| 1 |
Lee JY, Kang BY, Jung SJ, Kwak AW, Lee SO, Park JW, Joo SH, Yoon G, Lee MH, Shim JH. Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET. Biomol Ther (Seoul) 2023;31:200-9. [PMID: 36281696 DOI: 10.4062/biomolther.2022.113] [Reference Citation Analysis]
|
| 2 |
Chen R, Wang Z, Lu T, Liu Y, Ji Y, Yu Y, Tou F, Guo S. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma. Thorac Cancer 2023. [PMID: 36825773 DOI: 10.1111/1759-7714.14822] [Reference Citation Analysis]
|
| 3 |
Alipour M, Moghanibashi M, Naeimi S. Identification of Specific Genes for Adenocarcinoma and Squamous Cell of Lung Carcinoma by Bioinformatics Analysis.. [DOI: 10.21203/rs.3.rs-2569669/v1] [Reference Citation Analysis]
|
| 4 |
Larsen ME, Lyu H, Liu B. HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors. Chinese Medical Journal - Pulmonary and Critical Care Medicine 2023. [DOI: 10.1016/j.pccm.2022.12.001] [Reference Citation Analysis]
|
| 5 |
Ming H, Li B, Jiang J, Qin S, Nice EC, He W, Lang T, Huang C. Protein degradation: expanding the toolbox to restrain cancer drug resistance. J Hematol Oncol 2023;16:6. [PMID: 36694209 DOI: 10.1186/s13045-023-01398-5] [Reference Citation Analysis]
|
| 6 |
Yi M, He T, Wang K, Wei Y. Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis. Clinics (Sao Paulo) 2023;78:100152. [PMID: 36681071 DOI: 10.1016/j.clinsp.2022.100152] [Reference Citation Analysis]
|
| 7 |
Zou J, Lan H, Li W, Xie S, Tong Z, Song X, Wang C. Comprehensive Analysis of Circular RNA Expression Profiles in Gefitinib-Resistant Lung Adenocarcinoma Patients. Technol Cancer Res Treat 2022;21:15330338221139167. [PMID: 36537128 DOI: 10.1177/15330338221139167] [Reference Citation Analysis]
|
| 8 |
Yang HS, Cai HY, Shan SC, Chen TF, Zou JY, Abudurufu M, Luo HH, Lei YY, Ke ZF, Zhu Y. Methylation of N6 adenosine-related long noncoding RNA: effects on prognosis and treatment in 'driver-gene-negative' lung adenocarcinoma. Mol Oncol 2023;17:365-77. [PMID: 36221911 DOI: 10.1002/1878-0261.13323] [Reference Citation Analysis]
|
| 9 |
Li M, Yan C, Jiao Y, Xu Y, Bai C, Miao R, Jiang J, Liu J. Site-directed RNA editing by harnessing ADARs: advances and challenges. Funct Integr Genomics 2022. [DOI: 10.1007/s10142-022-00910-3] [Reference Citation Analysis]
|
| 10 |
Ravi R, Zeyaullah M, Ghosh S, Khan Warsi M, Baweja R, Alshahrani AM, Mishra A, Ahmad R. Use of gold nanoparticle-silibinin conjugates: A novel approach against lung cancer cells. Front Chem 2022;10:1018759. [DOI: 10.3389/fchem.2022.1018759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Tian X, Wang R, Gu T, Ma F, Laster KV, Li X, Liu K, Lee MH, Dong Z. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer. Mol Cancer 2022;21:193. [PMID: 36203195 DOI: 10.1186/s12943-022-01662-1] [Reference Citation Analysis]
|
| 12 |
Duffy MJ, Tang M, Rajaram S, O'Grady S, Crown J. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use? Cancers (Basel) 2022;14:4499. [PMID: 36139658 DOI: 10.3390/cancers14184499] [Reference Citation Analysis]
|
| 13 |
Zhou D, Luo X, Zhou Z, Zeng X, Wan X, Tan C, Liu Q. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. Front Pharmacol 2022;13:880280. [DOI: 10.3389/fphar.2022.880280] [Reference Citation Analysis]
|
| 14 |
Zhu RY, Chen H, Gao YJ, Pan ZH, Wang JY. Effects of psychological nursing care on anxiety and depression in perioperative patients with lung cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e29914. [PMID: 35866819 DOI: 10.1097/MD.0000000000029914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Lucas LM, Cullum RL, Markham JA, Woggerman JN, Dwivedi V, Mohamedelhassan RH, Cook LJ, Kelley CM, Knerr EL, Kaufmann DP, Jacobi MA, Taylor DC, Rael CC, Waits DS, Ghosh TM, Halanych KM, Gupta RB, Riese DJ. ERBB4 Mutant Alleles May Drive BRAF WT Melanomas.. [DOI: 10.1101/2022.06.21.22276707] [Reference Citation Analysis]
|
| 16 |
Lucas L, Cullum R, Dwivedi V, Markham J, Woggerman J, Kelley C, Knerr E, Cook L, Lucas H, Waits D, Ghosh T, Halanych K, Gupta R, Riese D. ERBB4 Drives the Proliferation of BRAF-WT Melanoma Cell Lines.. [DOI: 10.1101/2022.06.20.22276663] [Reference Citation Analysis]
|
| 17 |
Alamery S, Zargar S, Yaseen F, Wani TA, Siyal A. Evaluation of the Effect of Wheat Germ Oil and Olmutinib on the Thioacetamide-Induced Liver and Kidney Toxicity in Mice. Life (Basel) 2022;12:900. [PMID: 35743930 DOI: 10.3390/life12060900] [Reference Citation Analysis]
|
| 18 |
Wang JL, Fu YD, Gao YH, Li XP, Xiong Q, Li R, Hou B, Huang RS, Wang JF, Zhang JK, Lv JL, Zhang C, Li HW. Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China. Genes Environ 2022;44:17. [PMID: 35606799 DOI: 10.1186/s41021-022-00248-z] [Reference Citation Analysis]
|
| 19 |
Yang P, Qiao Y, Meng M, Zhou Q. Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer. Front Oncol 2022;12:864159. [PMID: 35574342 DOI: 10.3389/fonc.2022.864159] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Wu L, Yu Y, Xu L, Wang X, Zhou J, Wang Y. TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer. Front Genet 2022;13:881875. [DOI: 10.3389/fgene.2022.881875] [Reference Citation Analysis]
|
| 21 |
Wu CP, Hung CY, Murakami M, Wu YS, Lin CL, Huang YH, Hung TH, Yu JS, Ambudkar SV. P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells. Cancers (Basel) 2022;14:2341. [PMID: 35565470 DOI: 10.3390/cancers14092341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Hu S, Ge M, Zhang S, Jiang M, Hu K, Gao L. Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim-Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer. Front Oncol 2022;12:854596. [PMID: 35433443 DOI: 10.3389/fonc.2022.854596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
